Merck & Co Inc · News · TradingHolo

Merck & Co Inc · News · TradingHolo

MRK news

Headlines tagged to this company

US drugmakers turn to China for licensing deals

Reuters · 22 d ago

Merck signs up to $2.13B license deal with SciBrunch

Seeking Alpha · 22 d ago

Merck in License Pact Worth Up to $2.13 Billion With SciBrunch Therapeutics

Dow Jones Newswires · 22 d ago

Merck licenses SciBrunch cancer drug in deal worth up to $2.13 billion

Reuters · 22 d ago

Merck Enters Into Exclusive Global License Agreement With Scibrunch Therapeutics For Spr2015, An Investigational Oral Kras G12d (On) Inhibitor

Reuters · 22 d ago

Merck & Co., Inc., Rahway, N.J., USA Licenses KRAS G12D Drug, Books $400M Charge

TradingView · 22 d ago

Ifinatamab Deruxtecan Biologics License Application For Patients With Previously Treated Extensive-Stage Small Cell Lung Cancer Voluntarily Withdrawn

Reuters · 24 d ago

Merck, Daiichi Sankyo Withdraw Application for Accelerated Approval of Lung Cancer Treatment

Dow Jones Newswires · 24 d ago

Merck, Daiichi pull US application for second partnered cancer therapy

Reuters · 24 d ago

Merck, Daiichi Sankyo withdraw US application for lung cancer drug

Reuters · 24 d ago

Ifinatamab Deruxtecan Biologics License Application for Certain Patients with Previously Treated Extensive-Stage Small Cell Lung Cancer Voluntarily Withdrawn

BusinessWire · 24 d ago

Merck & Co., Inc. (MRK) Withdraws U.S. BLA for Ifinatamab Deruxtecan in ES-SCLC

TradingView · 24 d ago

Merck, Eisai Get FDA OK of Welireg/Lenvima Combo in Kidney Cancer

Dow Jones Newswires · 25 d ago

Stock Market Today, Aug. 19: Stocks Edge Higher, Ending 3-Day Losing Streak

Fool - Investing News · 62 d ago

Merck: Why Consolidation Looks Like The Next Move (Rating Downgrade)

Seeking Alpha · 62 d ago

Merck (MRK) Is Considered a Good Investment by Brokers: Is That True?

Zacks Investment Research · 75 d ago

U.S. FDA Accepts sBLA for ENFLONSIA™ (clesrovimab-cfor) to Update its Respiratory Syncytial Virus (RSV) Lower Respiratory Tract Disease Indication to Include Children Under Two Years at Increased Risk for Severe RSV for Their Second Season

Business Wire · 75 d ago

Merck & Co., Inc., Rahway, N.J., USA Announces Second-Quarter 2026 Financial Results; Highlights Key Regulatory and Clinical Milestones Across Broad, Diverse Pipeline

Business Wire · 77 d ago

← Previous More news →